EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Proteomic changes upon treatment with semaglutide in individuals with obesity

Lasse Maretty, Dipender Gill iD, Lotte Simonsen iD, Keng Soh, Loukas Zagkos iD, Michael Galanakis, Jonas Sibbesen, Miquel Triana Iglesias iD, Anna Secher iD, Dirk Valkenborg, Jonathan Q Purnell iD, Lotte Bjerre Knudsen iD und 2 weitere

Nature Medicine · 2025-01 · 31 (1) · 267-277

DOI: 10.1038/s41591-024-03355-2 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Nature Medicine, online erschienen am 03.01.2025. Verfasst von Lasse Maretty und 13 weiteren Autor:innen. Beteiligte Einrichtung: Data Science, Novo Nordisk A/S, Søborg, Denmark. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Obesity, Proteome. Die Arbeit wurde bisher 94-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk A/S.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obesity and type 2 diabetes are prevalent chronic diseases effectively managed by semaglutide. Here we studied the effects of semaglutide on the circulating proteome using baseline and end-of-treatment serum samples from two phase 3 trials in participants with overweight or obesity, with or without diabetes: STEP 1 ( n = 1,311) and STEP 2 ( n = 645). We identified evidence supporting broad effects of semaglutide, implicating processes related to body weight regulation, glycemic control, lipid metabolism and inflammatory pathways. Several proteins were regulated with semaglutide, after accounting for changes in body weight and HbA 1c at end of trial, suggesting effects of semaglutide on the proteome beyond weight loss and glucose lowering. A comparison of semaglutide with real-world proteomic profiles revealed potential benefits on disease-specific proteomic signatures including the downregulation of specific proteins associated with cardiovascular disease risk, supporting its reported effects of lowering cardiovascular disease risk and potential drug repurposing opportunities. This study showcases the potential of proteomics data gathered from randomized trials for providing insights into disease mechanisms and drug repurposing opportunities. These data also highlight the unmet need for, and importance of, examining proteomic changes in response to weight loss pharmacotherapy in future trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like PeptidesObesityProteomeProteomicsAdultFemaleHumansMaleMiddle AgedGlycated HemoglobinWeight LossClinical Trials, Phase III as TopicRandomized Controlled Trials as TopicObservational Studies as TopicGlucagon-Like Peptide 1Semaglutide

Substanzen

Glucagon-Like PeptidesGlycated HemoglobinProteomeGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Data Science, Novo Nordisk A/S, Søborg, Denmark.
  • QIAGEN A/S, Aarhus, Denmark.
  • Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
  • Sequoia Genetics, London, UK.
  • Obesity Research, Novo Nordisk A/S, Måløv, Denmark.
  • Center for Statistics and Data Science Institute, Hasselt University, Hasselt, Belgium.

ORCID-Profile: Dipender Gill, Lotte Simonsen, Loukas Zagkos, Miquel Triana Iglesias, Anna Secher, Jonathan Q Purnell, Lotte Bjerre Knudsen, Abd A Tahrani

Förderung

  • Novo Nordisk A/S

Zitieren

APA

Maretty, L., Gill, D., Simonsen, L., Soh, K., Zagkos, L., Galanakis, M., Sibbesen, J., Iglesias, M. T., Secher, A., Valkenborg, D., Purnell, J. Q., Knudsen, L. B., Tahrani, A. A., & Geybels, M. (2025). Proteomic changes upon treatment with semaglutide in individuals with obesity. Nature Medicine, 31(1), 267-277. https://doi.org/10.1038/s41591-024-03355-2

Vancouver

Maretty L, Gill D, Simonsen L, Soh K, Zagkos L, Galanakis M, et al. Proteomic changes upon treatment with semaglutide in individuals with obesity. Nature Medicine. 2025;31(1):267-277. doi:10.1038/s41591-024-03355-2

BibTeX
@article{Maretty2025,
  author = {Maretty, Lasse and Gill, Dipender and Simonsen, Lotte and Soh, Keng and Zagkos, Loukas and Galanakis, Michael and Sibbesen, Jonas and Iglesias, Miquel Triana and Secher, Anna and Valkenborg, Dirk and Purnell, Jonathan Q and Knudsen, Lotte Bjerre and Tahrani, Abd A and Geybels, Milan},
  title = {Proteomic changes upon treatment with semaglutide in individuals with obesity},
  journal = {Nature Medicine},
  year = {2025},
  volume = {31},
  number = {1},
  pages = {267--277},
  doi = {10.1038/s41591-024-03355-2}
}
Kostenlos starten →